AYTU BIOPHARMA, INC Restructuring Charges
AYTU BIOPHARMA, INC (AYTU) reported Restructuring Charges of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-09-22
- AYTU BIOPHARMA, INC restructuring charges for the quarter ending 2026-06-30 was $0.00.
- AYTU BIOPHARMA, INC restructuring charges for the quarter ending 2026-03-31 was $0.00.
- AYTU BIOPHARMA, INC restructuring charges for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC restructuring charges for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC restructuring charges for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC restructuring charges for fiscal 2025 was $2.10M, a 2.55% decline from fiscal 2024.
- AYTU BIOPHARMA, INC restructuring charges for fiscal 2024 was $2.16M.
- AYTU BIOPHARMA, INC restructuring charges for fiscal 2023 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 9 month as first filed | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 10-K · filed 2026-09-22 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-12-31 | $0.00 10-Q · filed 2026-02-03 | $0.00 10-Q · filed 2026-02-03 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $1.32M derived: sum of 4 quarters · filed 2026-09-22 | |||
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $1.32M derived: sum of 3 quarters · filed 2026-09-22 | $2.10M 10-K · filed 2026-09-22 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $1.32M derived: sum of 2 quarters · filed 2026-05-13 | $2.10M 10-Q · filed 2026-05-13 | $4.01M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $1.32M 10-Q · filed 2026-02-03 | $2.10M 10-Q · filed 2026-02-03 | $4.01M derived: sum of 3 quarters · filed 2026-02-03 | $4.26M derived: sum of 4 quarters · filed 2026-02-03 | |||
| 2024-09-30 | $784.00K 10-Q · filed 2025-11-13 | $2.70M derived: sum of 2 quarters · filed 2025-11-13 | $2.94M derived: sum of 3 quarters · filed 2025-11-13 | $2.94M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $2.16M derived: sum of 2 quarters · filed 2025-09-23 | $2.16M derived: sum of 3 quarters · filed 2025-09-23 | $2.16M 10-K · filed 2025-09-23 | $2.37M 10-K · filed 2024-09-26 | ||
| 2024-03-31 | $244.00K 10-Q · filed 2025-05-14 | $244.00K derived: sum of 2 quarters · filed 2025-05-14 | $244.00K 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $0.00 10-Q · filed 2025-02-12 | $0.00 10-Q · filed 2025-02-12 | |||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | $0.00 10-K · filed 2024-09-26 | ||||||
| 2022-06-30 | $0.00 10-K · filed 2022-09-27 | ||||||
| 2021-06-30 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $4.83M derived: sum of 2 quarters · filed 2022-09-27 | $4.89M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $4.82M 10-Q · filed 2022-05-16 | $4.82M 10-Q · filed 2021-05-17 | $4.88M 10-Q · filed 2022-05-16 | $4.87M 10-Q · filed 2021-05-17 | |||
| 2020-06-30 | $531.02K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $667.00K 10-K · filed 2021-09-28 | |||||
| 2020-03-31 | $135.98K 10-Q · filed 2021-05-17 | ||||||
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $1.51K 10-K · filed 2017-08-31 | |||||
| 2017-03-31 | $1.51K 10-Q · filed 2017-05-11 | ||||||
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $0.00 10-K · filed 2017-08-31 | |||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |